Pier Luigi Tazzari

Pier Luigi Tazzari publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Pier Luigi Tazzari sits on this spectrum.

Pier Luigi Tazzari D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Pier Luigi Tazzari sits on this spectrum.

Best Publications

• Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro

  Francesco Alviano;Valentina Fossati;Cosetta Marchionni;Mario Arpinati

  591
  Citations

• Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy.

  Francis J. Burrows;Elaine J. Derbyshire;Pier Luigi Tazzari;Peter Amlot

  457
  Citations

• CTLA‐4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction

  Elisabetta Contardi;Giulio L. Palmisano;Pier Luigi Tazzari;Alberto M. Martelli

  356
  Citations

• Nuclear apoptotic changes: An overview

  Alberto M. Martelli;Alberto M. Martelli;Marina Zweyer;Robert L. Ochs;Pier Luigi Tazzari

  213
  Citations

• Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

  Francesca Chiarini;Cecilia Grimaldi;Francesca Ricci;Pier Luigi Tazzari

  202
  Citations

• Thoracic aortas from multiorgan donors are suitable for obtaining resident angiogenic mesenchymal stromal cells.

  Gianandrea Pasquinelli;Pier Luigi Tazzari;Cristiana Vaselli;Laura Foroni

  157
  Citations

• Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.

  Andreas Engert;Francis Burrows;Wolfram Jung;Pier Luigi Tazzari

  150
  Citations

• Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.

  Francesca Chiarini;Federica Falà;Pier Luigi Tazzari;Francesca Ricci

  142
  Citations

• Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins.

  Andrea Bolognesi;Pier Luigi Tazzari;Fabiola Olivieri;Letizia Polito

  141
  Citations

• Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease

  Marco Andreani;Manuela Testi;Javid Gaziev;Rossella Condello

  136
  Citations

• Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas.

  S.A. Pileri;E. Sabattini;B. Falini;P.L. Tazzari

  132
  Citations

• Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes

  Lucia Catani;Maria Elena Fagioli;Pier Luigi Tazzari;Francesca Ricci

  127
  Citations

• Isolation, characterization and differentiation of mesenchymal stem cells from amniotic fluid, umbilical cord blood and Wharton's jelly in the horse.

  Eleonora Iacono;Lara Brunori;Alessandro Pirrone;Pasquale Paolo Pagliaro

  126
  Citations

• Interleukin-11 induces Th2 polarization of human CD4(+) T cells.

  Antonio Curti;Marina Ratta;Silvia Corinti;Giampiero Girolomoni

  124
  Citations

• Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells

  Pier Luigi Tazzari;Giovanna Tabellini;Francesca Ricci;Veronica Papa

  120
  Citations

• The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells

  Luca M Neri;Paola Borgatti;Pier Luigi Tazzari;Roberta Bortul

  113
  Citations

• Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.

  Pier Luigi Tazzari;Andrea Bolognesi;Daniela de Totero;Brunangelo Falini

  101
  Citations

• In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins

  A Bolognesi;L Polito;P L Tazzari;R M Lemoli

  98
  Citations

• Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.

  Roberta Bortul;Pier Luigi Tazzari;Anna Maria Billi;Giovanna Tabellini

  98
  Citations

• Identification of TLR4 as the Receptor That Recognizes Shiga Toxins in Human Neutrophils

  Maurizio Brigotti;Domenica Carnicelli;Valentina Arfilli;Nicola Tamassia

  98
  Citations